Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 13:8:269.
doi: 10.3389/fimmu.2017.00269. eCollection 2017.

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients

Danay Saavedra  1 , Tania Crombet  1
Affiliations
Review

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients

Danay Saavedra et al. Front Immunol. .

Abstract

Lung cancer is the common fatal illness with the highest incidence and mortality globally. Epidermal growth factor receptor overexpression by tumor cells is associated with uncontrolled proliferation, angiogenesis, anti-apoptotic signals, metastization, and invasiveness. CIMAvax-EGF vaccine consists of a chemical conjugate of the EGF with the P64 protein derived from the Meningitis B bacteria and Montanide ISA 51, as adjuvant. The vaccine is projected to induce antibodies against EGF that results in EGF withdrawal. CIMAvax-EGF demonstrated to be safe and immunogenic in advanced non-small cell lung cancer (NSCLC) patients. The efficacy study was an open-label, multicentric Phase III clinical trial, which enrolled 405 advanced NSCLC patients. Patients with proven stage IIIB/IV NSCLC, who had completed four to six cycles of chemotherapy (CTP) were randomized to receive CIMAvax-EGF or best supportive care. CIMAvax-EGF resulted in a significantly larger overall survival in patients receiving at least four doses. High EGF concentration at baseline was a good predictive biomarker of the vaccine activity and a poor prognostic biomarker for the non-treated population. The proportion of CD8+CD28- cells, CD4 cells, and the CD4/CD8 ratio after first-line CTP was also associated with CIMAvax-EGF clinical benefit. After completing the Phase III, a Phase IV trial was done where the vaccine was administered in primary care units. Administering the vaccine at primary care institutions granted better access and treatment compliance. Safety was confirmed. Several clinical trials are currently ongoing to validate EGF as a predictive biomarker of CIMAvax-EGF efficacy.

Keywords: CIMAvax-EGF; cancer vaccine; clinical trial; immunotherapy; non-small cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CIMAvax-EGF composition. CIMAvax-EGF therapeutic vaccine consist on a chemical conjugate of the EGF with the P64K protein derived from Neisseria meningitidis.
Figure 2
Figure 2
CIMAvax-EGF mechanism of action. Anti-EGF antibodies induced by CIMAvax-EGF inhibit EGF–epidermal growth factor receptor (EGFR) binding and abrogate EGFR activation.
See this image and copyright information in PMC

References

    1. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol (2015) 7:65–79.10.2147/RRU.S63447 - DOI - PMC - PubMed
    1. Snyder A, Zamarin D, Wolchok JD. Immunotherapy of melanoma. Prog Tumor Res (2015) 42:22–9.10.1159/000436998 - DOI - PubMed
    1. Chee J, Robinson BW, Holt RA, Creaney J. Immunotherapy of lung malignancies – from gene sequencing to novel therapies. Chest (2016).10.1016/j.chest.2016.10.007 - DOI - PubMed
    1. Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol (2016) 37(7):462–76.10.1016/j.it.2016.04.010 - DOI - PubMed
    1. Tsiatas M, Mountzios G, Curigliano G. Future perspectives in cancer immunotherapy. Ann Transl Med (2016) 4(14):273.10.21037/atm.2016.07.14 - DOI - PMC - PubMed